- Our Pipeline - Kezar Life Sciences Inc.
Investor Contact Email Alerts Careers Kezar Careers Join Our Team Job Opportunities
- Our Company - Kezar Life Sciences Inc.
At Kezar Life Sciences, we are developing first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways by targeting key intracellular proteins
- Executive Team - Kezar Life Sciences Inc.
Prior to founding Kezar, he was the Vice President of Research at Onyx Pharmaceuticals where he played a key leadership role in the discovery and development of 2 proteasome inhibitors, including carfilzomib (KYPROLIS™), currently approved for the treatment of multiple myeloma
- Selective Immuno-proteasome Inhibition - Kezar Life Sciences Inc.
Unlike other therapeutic options that target a single type of immune cell or cytokine, zetomipzomib (KZR-616), Kezar’s first-in-class, selective immunoproteasome inhibitor, is designed to modulate many elements of the immune system when it is dysregulated without direct immunosuppression
- Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and . . .
Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases
- Clinical Trials - Kezar Life Sciences Inc.
Kezar Life Sciences is committed to developing safe and effective therapies for serious diseases that impact patients and their families To achieve this, we conduct clinical trials to assess the risks and benefits of our investigational therapies
- Join Our Team - Kezar Life Sciences Inc.
Here at Kezar, our employees are our greatest asset and are the drivers of the Company’s success Every day, our team of passionate professionals are converting scientific ideas to first-in-class assets that have the potential for significant clinical impact in the most difficult-to-treat diseases
- Scientific Poster Templates - Kezar Life Sciences Inc.
AS is an advisor for AstraZeneca, BMS, Eli Lilly, GSK, and Kezar SVP is a consultant for Alexion, Aurinia, BMS, GSK, Kezar, and received a grant research grant from Aurinia, EMD-Serono, and NIH-NIDDK
|